"Through responding to posts added by other users on Crowdhelix, Universität des Saarlandes was able to connect to two separate European consortia with proposals under development that needed the expertise of Universität des Saarlandes based PIs. We're pleased with the collaborative partnerships we were able to achieve and await the pending evaluation results."

"I am happy to share I have recently been engaged by a colleague in Crowdhelix and after a few communications we joined the consortium and submitted a proposal together. We are now waiting for the results. On other occasions, I have been contacted right after posting, as well as interacting with people who have advertised or expressed interest in a particular call. I have shared Crowdhelix with the entire team in UNIVPM and we are happy be part of this platform."

"From my experience, Crowdhelix has worked very well for the University of Leeds' collaboration needs. We posted on their platform, on behalf of a Leeds based PI, about collaboration on a recent Horizon Europe submission. We were able to connect with strong consortium partners with whom to develop this proposal in time for the deadline. Crowdhelix also contributed to the development of the Impact section through the inclusion of their Helix Impact Model."

“Crowdhelix’s ‘Leveraging Science with AI Tools’ training event provided real-world practical strategies to enhance research efficiency and creativity. I gained valuable insights into brainstorming innovative ideas, streamlining workflows, and boosting outreach efforts. The session’s engaging and forward-thinking approach made it thoroughly enjoyable, and it highlighted Crowdhelix’s dedication to empowering researchers with cutting-edge tools and resources.”

“The recent webinar hosted by Crowdhelix was a notable success, providing researchers with essential tools and insights to elevate their collaborative projects. The workshop provided a comprehensive exploration of crafting impactful impact sections, with a particular emphasis on Horizon Europe destinations and key impact pathways. Attendees emerged from the webinar empowered with practical strategies and a deeper understanding, poised to develop stronger project proposals and collaborations. This achievement underscores Crowdhelix‘s dedication to fostering innovation and excellence.”

"After adding two posts to Crowdhelix in Autumn of 2024, I was able to source the relevant expertise and partners needed for one new proposal in the area of biomass fermentation, and one existing project needing an independent ethics advisor. It's great to have a platform like Crowdhelix at our disposal."

"Our Durham University based PI from the School of Modern Languages and Culture (MLAC) has been successful in securing €3.8 million for the RELISH (Reframing European gastronomy Legacy through Innovation, Sustainability and Heritage) project funded from the HORIZON-CL2-2024-HERITAGE-01-04 call. Through using Crowdhelix we were able to secure a key partner for our multi-disciplinary consortium that enabled the submission and contributed to the success of this proposal."

"Over the past two years I have successfully used Crowdhelix to find excellent partners for two Horizon Europe Mission Cancer calls. After posting in the Health and Mission Cancer Helixes, I was contacted by a number of potential partners that led to impactful collaboration and proposal development. I would recommend Crowdhelix as an outstanding open innovation tool to any ambitious researcher looking to collaborate internationally. My experience has been excellent."

Sabancı University Nanotechnology Research & Application Center worked with Crowdhelix and BC Partnering during the proposal preparation phase of the NanoBio4Can “Nanobiotechnologies for Innovative Therapeutic Approaches for Cancer” project. A top listed project, it received a budget of €3.8 million. NanoBio4Can will support the training of 24 international postdoctoral fellows who will work on the discovery of nanotechnological drugs and the development of treatment approaches against cancer.